Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 107; no. 4; pp. 1630 - 1635
• Main Authors: Jiang, Ying, Mullaney, Kerry A, Peterhoff, Corrinne M, Che, Shaoli, Schmidt, Stephen D, Boyer-Boiteau, Anne, Ginsberg, Stephen D, Cataldo, Anne M, Mathews, Paul M, Nixon, Ralph A
• Format: Journal Article
• Language: English
• Published: National Academy of Sciences 26.01.2010; National Acad Sciences
• Subjects: Alzheimer disease; Biological Sciences; Down syndrome; endosomes; fibroblasts; gene overexpression; genes; mutants; neurodegenerative diseases; small interfering RNA; therapeutics; trisomics
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.0908953107

An additional copy of the β-amyloid precursor protein (APP) gene causes early-onset Alzheimer's disease (AD) in trisomy 21 (DS). Endosome dysfunction develops very early in DS and AD and has been implicated in the mechanism of neurodegeneration. Here, we show that morphological and functional endocytic abnormalities in fibroblasts from individuals with DS are reversed by lowering the expression of APP or β-APP-cleaving enzyme 1 (BACE-1) using short hairpin RNA constructs. By contrast, endosomal pathology can be induced in normal disomic (2N) fibroblasts by overexpressing APP or the C-terminal APP fragment generated by BACE-1 (βCTF), all of which elevate the levels of βCTFs. Expression of a mutant form of APP that cannot undergo β-cleavage had no effect on endosomes. Pharmacological inhibition of APP γ-secretase, which markedly reduced Aβ production but raised βCTF levels, also induced AD-like endosome dysfunction in 2N fibroblasts and worsened this pathology in DS fibroblasts. These findings strongly implicate APP and the βCTF of APP, and exclude Aβ and the αCTF, as the cause of endocytic pathway dysfunction in DS and AD, underscoring the potential multifaceted value of BACE-1 inhibition in AD therapeutics.